MagForce NT GmbH

What MagForce NT GmbH does

MagForce NT GmbH (operating commercially as Nanotherm Therapeutics) is a medical device company developing nanotechnology-based thermal ablation therapies for solid tumors. Its core platform consists of two integrated components: Nanotherm®AS1, bioengineered non-toxic nanoparticles delivered directly into tumor tissue via a universal 19G needle, and the NanoActivator™, an RF energy device that generates a contactless alternating magnetic field to heat the nanoparticles and produce a predictable, controlled ablation zone. The company's proprietary 2-step image-guided workflow — Deliver, Confirm, Predict, Activate, Ablate — uses standard imaging (CT, EBUS, CBCT) to visualize nanoparticle deposits before activation, allowing the ablation zone to be defined in advance and reducing collateral damage to adjacent healthy tissue. The contactless energy delivery is designed to be insensitive to patient motion (breathing and heartbeat), addressing a key limitation of conventional antenna-based ablation methods.

The company has accumulated more than 25 years of research and development, supported by over 100 patents globally, ISO 13485:2016 quality certification, and clinical experience in 200+ patients with over 1,000 activations across 3 active clinical research centers. It operates through a Delaware-incorporated U.S. entity (Nanotherm Therapeutics Inc., Wilmington, DE) and a German operating entity (Nanotherm Therapeutics GmbH, Berlin). Financing to date has come from a mix of equity and debt instruments, including a $15 million round led by Heliad AG and Mithril Capital Management in 2014, a $5.66 million round led by Apeiron Investment Group in 2020, and up to EUR 3.5 million in senior bearer notes issued to Lansdowne Investment Company Cyprus Limited in 2022.

Commercially, MagForce NT GmbH is pre-revenue: the Nanotherm system is an investigational device and is not approved for commercial clinical use in any jurisdiction, and prior CE marking in the European Union has been discontinued. The company engages the market through a consultative, demo-driven GTM motion targeting oncology and interventional-radiology departments at clinical research centers, with the strategic intent of progressing regulatory milestones toward eventual commercial authorization. Leadership includes CEO Ben J. Lipps, COO Hoda Tawfik, and Safety Officer & Risk Manager Eva Steier.

Name

MagForce NT GmbH

Legal name

Nanotherm Therapeutics Inc.

Website

https://magforce.de

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

51–100 employees

Short description

MagForce NT GmbH (Nanotherm Therapeutics) is a pre-revenue medical device company developing Nanotherm®AS1 nanoparticles and the NanoActivator™ RF system for contactless, image-guided thermal ablation of solid tumors, targeting oncology departments and clinical research centers.

Ownership category

akta.pro rank

Product category

Nanoparticle Thermal Ablation Systems

NAICS

Research and Development in Nanotechnology (541713), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Nanoparticle cancer therapy
• Thermal tumor ablation
• Medical device oncology
• Magnetic nanoparticle treatment
• Interventional oncology devices

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Commercialization (Future): As the Nanotherm system is an investigational device not yet approved for commercial clinical use in any jurisdiction, the company is currently pre-revenue. Future revenue is expected to come from sale or licensing of the Nanotherm system (NanoActivator device and AS1 nanoparticles) to clinical treatment centers.
2. Technology Licensing (Future): Potential revenue from licensing the proprietary nanoparticle technology and ablation methodology to medical device partners or healthcare institutions. The company holds over 100 patents across key global markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

MagForce NT GmbH (operating as Nanotherm Therapeutics) develops and manufactures a nanoparticle-based thermal ablation system for the treatment of solid tumors. The platform consists of Nanotherm®AS1 bioengineered nanoparticles injected directly into tumor tissue and the NanoActivator™ RF energy device that generates a contactless alternating magnetic field to heat the nanoparticles and ablate the tumor within a predictable zone. The technology is currently investigational and not approved for commercial clinical use in any jurisdiction.

Product overview

Nanotherm Therapeutics (MagForce NT GmbH) offers a unified thermal ablation platform consisting of two integrated components: the Nanotherm®AS1 bioengineered nanoparticles delivered directly into tumor tissue via a universal 19G needle, and the NanoActivator™ device that generates an alternating magnetic field to heat the nanoparticles and ablate target tissue within a predictable, controlled zone. The platform uses a 2-step image-guided therapy workflow (Deliver-Confirm-Predict-Activate-Ablate) to achieve targeted thermal ablation of solid tumors with reduced collateral damage to adjacent structures.

Differentiator

Problem solved

Functional benefit

Brands

• Nanotherm®AS1: Bioengineered non-toxic nanoparticles placed into tumor tissue that remain in place due to their coating for targeted thermal ablation.
• NanoActivator™

Products and services

• Nanotherm®AS1

Quantifiable outcome

• 200+ patients treated with over 1000 activations demonstrating clinical safety and efficacy
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Monteris Medical: Maker of NeuroBlate, a minimally invasive laser interstitial thermal therapy (LITT) system for brain tumors; relevant analogue given MagForce's historical brain tumor (glioblastoma) research focus.
• EDAP TMS: Developer of Focal One HIFU platform for prostate cancer ablation—competes directly in the prostate indication using a different energy modality (high-intensity focused ultrasound).
• InSightec: Pioneer in MR-guided focused ultrasound (MRgFUS) for non-invasive tissue ablation; shares Nanotherm's image-guided, motion-management narrative across oncology and other indications.
• Nanobiotix: Clinical-stage nanomedicine company developing NBTXR3 radioenhancer nanoparticles for solid tumors; comparable as a nanoparticle-platform oncology company pursuing novel mechanism approaches.

Broad incumbents

• Medtronic: Dominant incumbent in RF ablation (Cool-tip) and microwave ablation (Emprint) across multiple oncology indications; represents the entrenched standard of care that Nanotherm must displace.
• AngioDynamics: Offers NanoKnife (irreversible electroporation) alongside RF and microwave ablation products—a relevant competitor in soft tissue ablation with a similarly novel mechanism story to Nanotherm.
• Boston Scientific: Major medtech with broad RF/microwave ablation portfolio and interventional oncology presence; competes for the same hospital procurement budgets and interventional radiology workflow slots.
• Johnson & Johnson (Ethicon / NeuWave): Ethicon's NeuWave microwave ablation system and broader interventional oncology portfolio represent a well-funded incumbent competitor in solid tumor ablation.

Direct peers

• Profound Medical: Commercial-stage TULSA-PRO system uses transurethral MR-guided ultrasound for prostate tissue ablation—a competing minimally-invasive thermal ablation modality in the same primary indication (prostate cancer).
• Nanospectra Biosciences: Developer of AuroLase, a gold nanoshell-mediated photothermal ablation therapy for prostate cancer—the closest direct analogue to MagForce's nanoparticle thermal ablation approach in both modality and indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/magforce-nt-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MagForce NT GmbH